BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
Canada's Serene Lakeside Mountain Village Is A Breathtaking Oasis For Outdoor Adventure- Help Your Insusceptibility: Good dieting and Way of life Tips
- Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- FDA official discusses potential link between COVID-19 vaccines and pediatric deaths
- California officials warn against foraging wild mushrooms after deadly poisoning outbreak
- The most effective method to Boost Eco-friendliness in Your Volvo XC40
- vote in favor of Your #1 kind of climate
- The Most Compelling Innovation Developments Somewhat recently
- Mali and Canadian miner Barrick agree to resolve tax dispute, ending 2-year standoff
